Global drug shortages are rising, yet pharmaceutical companies, national authorities, and investors lack visibility into the upstream supply chain risks that cause them. Trade data is fragmented, firm-level data is confidential, and disruptions from geopolitics to manufacturing failures cascade unpredictably across borders.
We are an ETH team of complexity scientists and resilience experts building a federated risk intelligence platform that maps global pharmaceutical supply chains and forecasts disruptions. Our solution supports the pharmaceutical industry, regulators, and hedge funds in assessing drug-level and company-level risk. The addressable market exceeds CHF 2B in pharma intelligence and financial risk analytics.
